Gene info: ID 8850

Gene: KAT2B

GENE ID: 8850

Synonyms: CAF|P/CAF|PCAF

Description: lysine acetyltransferase 2B

Gene type: protein-coding

Location: 3p24.3

dbXrefs: Ensembl:ENSG00000114166 MIM:602303 Vega:OTTHUMG00000130481 UniprotKB:Q92831

RefSeq: NC_000003.12

Retrived from: PubMed|SNP Mapped

SNPs: 1 ANCO-SNPs

Phenotype: ND|AD

# Publications: 2

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 6.339e-1 (AD) 6.320e-2 (ND)

ANCO-SNPs

SNP ID	Position	Alleles	Trait	Variation Type
rs17678713	chr3:20151277 (GRCh38.p7)	G>A	alcohol dependence	SNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
ADD3	0.938
QKI	0.93
EFCAB14	0.906
MTMR10	0.892
IL6ST	0.891
SEPT2	0.89
PON2	0.89
SASH1	0.884
RHOBTB3	0.881
PSAT1	0.879

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
RHO	-0.521
RTP1	-0.508
CALHM1	-0.494
ADRA1D	-0.491
MCHR1	-0.49
OR4F29	-0.486
ABCC12	-0.484
OPRD1	-0.477
OVOL2	-0.477
PRSS16	-0.472

ID	Drug Name	Drug Type	CAS Num	Status	Role
DB01992	Coenzyme A	Small Molecule	85-61-0	Investigational\|Nutraceutical	Target
DB08186	(3E)-4-(1-METHYL-1H-INDOL-3-YL)BUT-3-EN-2-ONE	Small Molecule		Experimental	Target
DB08291	N-(3-AMINOPROPYL)-2-NITROBENZENAMINE	Small Molecule		Experimental	Target

ID	Drug Name	Action	PubMed
C031763	1,3-butadiene	"1,3-butadiene results in increased expression of KAT2B mRNA"	25237060
C028474	1,4-bis(2-(3,5-dichloropyridyloxy))benzene	"1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in decreased expression of KAT2B mRNA"	22698814
C111118	2',3,3',4',5-pentachloro-4-hydroxybiphenyl	"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of KAT2B mRNA"	19114083
C016403	2,4-dinitrotoluene	"2,4-dinitrotoluene affects the expression of KAT2B mRNA"	21346803
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT2B mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT2B mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT2B mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT2B mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT2B mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT2B mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT2B mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT2B mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT2B mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT2B mRNA"	27188386
D000082	Acetaminophen	Acetaminophen results in increased expression of KAT2B mRNA	22230336
D000082	Acetaminophen	Acetaminophen affects the expression of KAT2B mRNA	17562736
D000105	Acetyl Coenzyme A	Acetyl Coenzyme A binds to KAT2B protein	28077572
D020106	Acrylamide	Acrylamide results in decreased expression of KAT2B mRNA	28959563
D000643	Ammonium Chloride	Ammonium Chloride results in increased expression of KAT2B protein	16483693
C006632	arsenic trioxide	arsenic trioxide results in increased expression of KAT2B mRNA	20458559
D001280	Atrazine	Atrazine results in decreased expression of KAT2B mRNA	22378314
C022921	benzo(k)fluoranthene	benzo(k)fluoranthene results in decreased expression of KAT2B mRNA	26377693
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of KAT2B mRNA	21714911
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of KAT2B mRNA	22228805
D004958	Estradiol	Estradiol affects the reaction [TNF protein promotes the reaction [KAT2B protein binds to IL6 promoter]]	24771768
D004958	Estradiol	[Estradiol co-treated with Tetrachlorodibenzodioxin] results in increased expression of KAT2B mRNA	19619570
D004958	Estradiol	Estradiol results in increased expression of KAT2B mRNA	19619570
D004958	Estradiol	Estradiol results in decreased expression of KAT2B mRNA	25210133
C006780	bisphenol A	bisphenol A affects the expression of KAT2B mRNA	20170705
C006780	bisphenol A	[potassium bromate co-treated with bisphenol A] affects the expression of KAT2B mRNA	27082013
C006780	bisphenol A	[XRCC6 gene mutant form results in increased susceptibility to potassium bromate] affects the reaction [[potassium bromate co-treated with bisphenol A] affects the expression of KAT2B mRNA]	27082013
C006780	bisphenol A	bisphenol A results in decreased expression of KAT2B mRNA	25181051
D000069286	Bortezomib	Bortezomib results in decreased expression of KAT2B mRNA	20471514
D001966	Bromine	Bromine results in decreased expression of KAT2B mRNA	21391292
C018475	butyraldehyde	butyraldehyde results in decreased expression of KAT2B mRNA	26079696
C024343	butyryl-coenzyme A	butyryl-coenzyme A binds to KAT2B protein	28077572
D002104	Cadmium	Cadmium results in decreased expression of KAT2B mRNA	24376830
D000074262	Canola Oil	Canola Oil affects the expression of KAT2B mRNA	16177195
D003065	Coenzyme A	Coenzyme A binds to KAT2B protein	28077572
D003375	Coumestrol	[Coumestrol co-treated with resveratrol] results in decreased expression of KAT2B mRNA	19167446
D003375	Coumestrol	Coumestrol results in decreased expression of KAT2B mRNA	19167446
D003471	Cuprizone	Cuprizone results in decreased expression of KAT2B mRNA	27523638
D016572	Cyclosporine	Cyclosporine results in decreased expression of KAT2B mRNA	20106945\|2556210
D016572	Cyclosporine	Cyclosporine results in decreased methylation of KAT2B promoter	27989131
C014347	decitabine	decitabine promotes the reaction [KAT2B protein binds to TP53 protein]	17977830
D003907	Dexamethasone	Dexamethasone inhibits the reaction [RX3 gene mutant form affects the expression of KAT2B mRNA]	27941970
D003907	Dexamethasone	Dexamethasone results in increased expression of KAT2B mRNA	19022236
D003993	Dibutyl Phthalate	Dibutyl Phthalate results in increased expression of KAT2B mRNA	21266533
D003997	Dicarbethoxydihydrocollidine	Dicarbethoxydihydrocollidine results in decreased expression of KAT2B mRNA	18098314
D002945	Cisplatin	[Cisplatin co-treated with jinfukang] results in decreased expression of KAT2B mRNA	27392435
D002945	Cisplatin	Cisplatin results in increased expression of KAT2B mRNA	21151649
D004052	Diethylnitrosamine	Diethylnitrosamine results in decreased expression of KAT2B mRNA	19638242
D004147	Dioxins	Dioxins promotes the reaction [KAT2B protein binds to CYP1A1 enhancer]	20631054
D004147	Dioxins	Dioxins promotes the reaction [KAT2B protein binds to CYP1B1 enhancer]	20631054
D004317	Doxorubicin	Doxorubicin results in increased expression of KAT2B mRNA	16001973
C118739	entinostat	entinostat results in decreased expression of KAT2B mRNA	26272509
C118739	entinostat	"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT2B mRNA"	27188386
C045651	epigallocatechin gallate	[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KAT2B mRNA	22079256
D004997	Ethinyl Estradiol	Ethinyl Estradiol affects the expression of KAT2B mRNA	20170705\|2686566
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in decreased expression of KAT2B mRNA	18936297
D004997	Ethinyl Estradiol	Ethinyl Estradiol affects the expression of KAT2B mRNA	20170705\|2686566
C024565	ethylene dichloride	ethylene dichloride results in decreased expression of KAT2B mRNA	28189721
D005020	Ethyl Methanesulfonate	Ethyl Methanesulfonate results in increased expression of KAT2B mRNA	23649840
C065180	fluvastatin	[zoledronic acid co-treated with fluvastatin] results in increased expression of KAT2B mRNA	16996129
D005557	Formaldehyde	Formaldehyde results in increased expression of KAT2B mRNA	23649840
D019833	Genistein	Genistein results in decreased expression of KAT2B mRNA	26865667
D005839	Gentamicins	Gentamicins results in decreased expression of KAT2B mRNA	22061828
D005897	Glafenine	Glafenine results in decreased expression of KAT2B mRNA	24136188
D005947	Glucose	[INS protein co-treated with Glucose] results in decreased expression of KAT2B mRNA	22634610
D017313	Fenretinide	Fenretinide results in decreased expression of KAT2B mRNA	28973697
D006861	Hydrogen Peroxide	Hydrogen Peroxide results in increased expression of KAT2B mRNA	15458575
D006918	Hydroxyurea	Hydroxyurea results in increased expression of KAT2B mRNA	27208086
C492448	ICG 001	ICG 001 results in decreased expression of KAT2B mRNA	26191083
C051890	irinotecan	irinotecan analog results in increased expression of KAT2B mRNA	18927307
C050106	isobutyryl-coenzyme A	isobutyryl-coenzyme A binds to KAT2B protein	28077572
C544151	jinfukang	[Cisplatin co-treated with jinfukang] results in decreased expression of KAT2B mRNA	27392435
C544151	jinfukang	jinfukang results in decreased expression of KAT2B mRNA	27392435
C561695	(+)-JQ1 compound	(+)-JQ1 compound results in increased expression of KAT2B mRNA	22802445\|2479639
C018584	linalool	linalool inhibits the reaction [KAT2B protein binds to HMGCR promoter]	21944868
C482199	lipopolysaccharide, E coli O55-B5	"lipopolysaccharide, E coli O55-B5 results in increased expression of KAT2B mRNA"	24972896
D008727	Methotrexate	Methotrexate promotes the reaction [E2F1 protein binds to KAT2B protein]	22484375
D008727	Methotrexate	Methotrexate results in increased expression of KAT2B mRNA	21678067
C004925	methylmercuric chloride	methylmercuric chloride results in decreased expression of KAT2B mRNA	28001369
D008741	Methyl Methanesulfonate	Methyl Methanesulfonate results in increased expression of KAT2B mRNA	23649840
D008777	Methyltestosterone	Methyltestosterone results in increased expression of KAT2B mRNA	29191790
D015741	Metribolone	[Metribolone binds to and affects the folding of AR protein] inhibits the reaction [AR protein modified form binds to KAT2B protein modified form]	28751236
D009151	Mustard Gas	Mustard Gas results in decreased expression of KAT2B mRNA	26392148
D037742	Nanotubes, Carbon	"Nanotubes, Carbon results in increased expression of KAT2B mRNA"	25554681
C119536	nickel acetate	NFE2L2 protein inhibits the reaction [nickel acetate results in increased expression of KAT2B mRNA]	23023193
C119536	nickel acetate	nickel acetate results in decreased expression of KAT2B mRNA	23023193
C022838	nickel chloride	nickel chloride affects the expression of KAT2B mRNA	22546817
C496932	panobinostat	"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT2B mRNA"	27188386
C496932	panobinostat	panobinostat results in decreased expression of KAT2B mRNA	26272509
C016030	pantogab	pantogab results in decreased expression of KAT2B mRNA	17379144
D010269	Paraquat	Paraquat results in increased expression of KAT2B mRNA	15458575
D010426	Pentosan Sulfuric Polyester	Pentosan Sulfuric Polyester results in increased expression of KAT2B mRNA	28973697
C076994	perfluorooctane sulfonic acid	perfluorooctane sulfonic acid results in decreased expression of KAT2B mRNA	27153767
D010634	Phenobarbital	Phenobarbital affects the expression of KAT2B mRNA	23091169
D010634	Phenobarbital	Phenobarbital results in decreased expression of KAT2B mRNA	19363144
D010662	Phenylmercuric Acetate	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT2B mRNA"	27188386
D010662	Phenylmercuric Acetate	Phenylmercuric Acetate results in decreased expression of KAT2B mRNA	26272509
C019536	potassium bromate	[potassium bromate co-treated with bisphenol A] affects the expression of KAT2B mRNA	27082013
C019536	potassium bromate	[XRCC6 gene mutant form results in increased susceptibility to potassium bromate] affects the reaction [[potassium bromate co-treated with bisphenol A] affects the expression of KAT2B mRNA]	27082013
C027373	potassium chromate(VI)	[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KAT2B mRNA	22079256
C027373	potassium chromate(VI)	potassium chromate(VI) results in decreased expression of KAT2B mRNA	22079256\|2271453
C045950	propiconazole	propiconazole results in decreased expression of KAT2B mRNA	19363144\|2127805
D054328	Proton Pump Inhibitors	Proton Pump Inhibitors results in decreased expression of KAT2B mRNA	25626140
D011794	Quercetin	Quercetin results in increased expression of KAT2B mRNA	21632981
C059514	resveratrol	[Coumestrol co-treated with resveratrol] results in decreased expression of KAT2B mRNA	19167446
C059514	resveratrol	resveratrol affects the reaction [TNF protein promotes the reaction [KAT2B protein binds to IL6 promoter]]	24771768
C059514	resveratrol	resveratrol results in increased expression of KAT2B mRNA	15767336
C009277	sodium arsenate	sodium arsenate results in decreased expression of KAT2B protein	26193056
C017947	sodium arsenite	sodium arsenite results in decreased expression of KAT2B mRNA	19822182
D018038	Sodium Selenite	Sodium Selenite results in decreased expression of KAT2B mRNA	18175754
C016766	sulforafan	sulforafan results in increased expression of KAT2B mRNA	26833863
D013481	Superoxides	KAT2B protein results in decreased abundance of Superoxides	25440059
D000952	Antigens, Polyomavirus Transforming	"Antigens, Polyomavirus Transforming results in increased expression of KAT2B mRNA"	26680231
C045037	testosterone-3-carboxymethyloxime-bovine serum albumin conjugate	testosterone-3-carboxymethyloxime-bovine serum albumin conjugate affects the expression of KAT2B mRNA	20189893
D013749	Tetrachlorodibenzodioxin	[Estradiol co-treated with Tetrachlorodibenzodioxin] results in increased expression of KAT2B mRNA	19619570
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of KAT2B mRNA	19619570\|2010694
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of KAT2B mRNA	21570461
D013849	Thimerosal	Thimerosal results in increased expression of KAT2B mRNA	27188386
C496197	trans-10,cis-12-conjugated linoleic acid	"trans-10,cis-12-conjugated linoleic acid results in decreased expression of KAT2B mRNA"	17951470
D014212	Tretinoin	KAT2B protein promotes the reaction [Tretinoin results in increased expression of CCL2 mRNA]	28053092
D014212	Tretinoin	KAT2B protein promotes the reaction [Tretinoin results in increased expression of FGR mRNA]	28053092
D014212	Tretinoin	KAT2B protein promotes the reaction [Tretinoin results in increased expression of ITGAM mRNA]	28053092
D014212	Tretinoin	KAT2B protein promotes the reaction [Tretinoin results in increased expression of ITGAM protein]	28053092
D014212	Tretinoin	Tretinoin inhibits the reaction [[KAT2B protein binds to MAPK3 promoter] which affects the expression of MAPK3 mRNA]	16050810
D014212	Tretinoin	Tretinoin results in increased expression of KAT2B mRNA	28053092
D014212	Tretinoin	Tretinoin results in increased expression of KAT2B protein	28053092
D014212	Tretinoin	Tretinoin affects the reaction [KAT2B protein binds to NR2C1 promoter]	17389641
C032910	triadimefon	triadimefon results in decreased expression of KAT2B mRNA	19363144
C012589	trichostatin A	"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT2B mRNA"	27188386
C012589	trichostatin A	trichostatin A affects the localization of KAT2B protein	15647279
C012589	trichostatin A	trichostatin A promotes the reaction [KAT2B protein binds to TGFBR2 promoter]	15647279
C012589	trichostatin A	trichostatin A results in decreased expression of KAT2B mRNA	22723015\|2493525
C012589	trichostatin A	trichostatin A results in increased expression of KAT2B mRNA	24935251
C016805	tris(1,3-dichloro-2-propyl)phosphate	"tris(1,3-dichloro-2-propyl)phosphate results in decreased expression of KAT2B mRNA"	26743178
C013320	tris(2-butoxyethyl) phosphate	tris(2-butoxyethyl) phosphate affects the expression of KAT2B mRNA	29024780
D014415	Tunicamycin	Tunicamycin results in increased expression of KAT2B mRNA	15458575
D014415	Tunicamycin	Tunicamycin results in increased expression of KAT2B mRNA	17127020
D014520	Urethane	Urethane results in increased expression of KAT2B mRNA	28818685
D014635	Valproic Acid	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT2B mRNA"	27188386
D014635	Valproic Acid	Valproic Acid results in decreased expression of KAT2B mRNA	23179753\|2438349
D014635	Valproic Acid	Valproic Acid results in decreased methylation of KAT2B gene	29154799
D014750	Vincristine	Vincristine results in increased expression of KAT2B mRNA	16001973
C088658	zoledronic acid	[zoledronic acid co-treated with fluvastatin] results in increased expression of KAT2B mRNA	16996129

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0000977	RNA polymerase II regulatory region sequence-specific DNA binding	-	IEA	-
GO:0003682	chromatin binding	-	ISS	-
GO:0003712	transcription coregulator activity	-	IPI	8684459
GO:0003713	transcription coactivator activity	-	IDA	12435739 14645221
GO:0004402	histone acetyltransferase activity	-	EXP	23555303
GO:0004402	histone acetyltransferase activity	-	IDA	14645221
GO:0004402	histone acetyltransferase activity	-	IMP	16829519
GO:0004468	lysine N-acetyltransferase activity, acting on acetyl phosphate as donor	-	IDA	19303849 19470756 23932781
GO:0004468	lysine N-acetyltransferase activity, acting on acetyl phosphate as donor	-	ISS	-
GO:0004861	cyclin-dependent protein serine/threonine kinase inhibitor activity	-	ISS	-
GO:0005515	protein binding	-	IPI	8684459 9674425 9687513 11568182 11744716 12163591 12435739 12743606 12813456 12887892 14645221 15273251 16322561 16332960 16415179 16543236 16617118 17301242 18504427 19188449 19303849 19407811 22575646 23932781 24492005 24825348 27796307 29174768
GO:0008134	transcription factor binding	-	IPI	15509593 17301242 17505058
GO:0016407	acetyltransferase activity	-	IDA	8684459 15273251 17301242
GO:0019901	protein kinase binding	-	ISS	-
GO:0042826	histone deacetylase binding	-	IPI	12887892
GO:0044877	protein-containing complex binding	-	IDA	17707232
GO:0061733	peptide-lysine-N-acetyltransferase activity	-	IDA	27796307 29174768

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0006338	chromatin remodeling	-	IDA	17707232
GO:0006338	chromatin remodeling	-	NAS	10365964
GO:0006367	transcription initiation from RNA polymerase II promoter	-	TAS	-
GO:0006473	protein acetylation	-	IDA	15273251
GO:0007050	cell cycle arrest	-	TAS	8684459
GO:0007219	Notch signaling pathway	-	TAS	-
GO:0007221	positive regulation of transcription of Notch receptor target	-	TAS	-
GO:0007507	heart development	-	ISS	-
GO:0008285	negative regulation of cell proliferation	-	IDA	8684459
GO:0010835	regulation of protein ADP-ribosylation	-	IDA	19470756
GO:0016032	viral process	-	IEA	-
GO:0018076	N-terminal peptidyl-lysine acetylation	-	IDA	12435739
GO:0018393	internal peptidyl-lysine acetylation	-	IDA	23932781 27796307 29174768
GO:0018394	peptidyl-lysine acetylation	-	IDA	19303849 19470756
GO:0032869	cellular response to insulin stimulus	-	IDA	19303849
GO:0035948	positive regulation of gluconeogenesis by positive regulation of transcription from RNA polymerase II promoter	-	IEA	-
GO:0043966	histone H3 acetylation	-	IDA	18838386
GO:0043970	histone H3-K9 acetylation	-	IEA	-
GO:0045652	regulation of megakaryocyte differentiation	-	TAS	-
GO:0045736	negative regulation of cyclin-dependent protein serine/threonine kinase activity	-	IEA	-
GO:0045747	positive regulation of Notch signaling pathway	-	TAS	-
GO:0045815	positive regulation of gene expression, epigenetic	-	TAS	-
GO:0045944	positive regulation of transcription by RNA polymerase II	-	IDA	19470756
GO:0046600	negative regulation of centriole replication	-	IDA	27796307
GO:0048511	rhythmic process	-	IEA	-
GO:0060173	limb development	-	ISS	-

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0000125	PCAF complex	-	NAS	17707232
GO:0000776	kinetochore	-	IEA	-
GO:0005634	nucleus	-	IDA	27796307
GO:0005634	nucleus	-	ISS	-
GO:0005654	nucleoplasm	-	TAS	-
GO:0005671	Ada2/Gcn5/Ada3 transcription activator complex	-	IDA	18838386
GO:0005813	centrosome	-	IDA	27796307
GO:0031672	A band	-	IEA	-
GO:0031674	I band	-	IEA	-
GO:0032991	protein-containing complex	-	IDA	15273251
GO:0042641	actomyosin	-	IEA	-

KEGG ID	KEGG Term
hsa04330	Notch signaling pathway

Reactome ID	Reactome Term	Evidence
R-HSA-157118	Signaling by NOTCH	IEA
R-HSA-157118	Signaling by NOTCH	TAS
R-HSA-162582	Signal Transduction	IEA
R-HSA-162582	Signal Transduction	TAS
R-HSA-1643685	Disease	TAS
R-HSA-1912408	Pre-NOTCH Transcription and Translation	IEA
R-HSA-1912408	Pre-NOTCH Transcription and Translation	TAS
R-HSA-1912422	Pre-NOTCH Expression and Processing	IEA
R-HSA-1912422	Pre-NOTCH Expression and Processing	TAS
R-HSA-1980143	Signaling by NOTCH1	IEA
R-HSA-1980143	Signaling by NOTCH1	TAS
R-HSA-2032785	YAP1- and WWTR1 (TAZ)-stimulated gene expression	TAS
R-HSA-212165	Epigenetic regulation of gene expression	TAS
R-HSA-2122947	NOTCH1 Intracellular Domain Regulates Transcription	IEA
R-HSA-2122947	NOTCH1 Intracellular Domain Regulates Transcription	TAS
R-HSA-212436	Generic Transcription Pathway	IEA
R-HSA-212436	Generic Transcription Pathway	TAS
R-HSA-2644602	Signaling by NOTCH1 PEST Domain Mutants in Cancer	TAS
R-HSA-2644603	Signaling by NOTCH1 in Cancer	TAS
R-HSA-2644606	Constitutive Signaling by NOTCH1 PEST Domain Mutants	TAS
R-HSA-2894858	Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer	TAS
R-HSA-2894862	Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants	TAS
R-HSA-3214847	HATs acetylate histones	IEA
R-HSA-3247509	Chromatin modifying enzymes	IEA
R-HSA-350054	Notch-HLH transcription pathway	TAS
R-HSA-392499	Metabolism of proteins	TAS
R-HSA-397014	Muscle contraction	TAS
R-HSA-4839726	Chromatin organization	IEA
R-HSA-5250913	Positive epigenetic regulation of rRNA expression	TAS
R-HSA-5250924	B-WICH complex positively regulates rRNA expression	TAS
R-HSA-5576891	Cardiac conduction	TAS
R-HSA-5578768	Physiological factors	TAS
R-HSA-5663202	Diseases of signal transduction	TAS
R-HSA-5688426	Deubiquitination	TAS
R-HSA-5689901	Metalloprotease DUBs	TAS
R-HSA-597592	Post-translational protein modification	TAS
R-HSA-73762	RNA Polymerase I Transcription Initiation	IEA
R-HSA-73854	RNA Polymerase I Promoter Clearance	IEA
R-HSA-73857	RNA Polymerase II Transcription	IEA
R-HSA-73857	RNA Polymerase II Transcription	TAS
R-HSA-73864	RNA Polymerase I Transcription	IEA
R-HSA-74160	Gene expression (Transcription)	IEA
R-HSA-74160	Gene expression (Transcription)	TAS
R-HSA-8878159	Transcriptional regulation by RUNX3	IEA
R-HSA-8878159	Transcriptional regulation by RUNX3	TAS
R-HSA-8878171	Transcriptional regulation by RUNX1	TAS
R-HSA-8936459	RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function	TAS
R-HSA-8939211	ESR-mediated signaling	TAS
R-HSA-8941856	RUNX3 regulates NOTCH signaling	IEA
R-HSA-8941856	RUNX3 regulates NOTCH signaling	TAS
R-HSA-9006931	Signaling by Nuclear Receptors	TAS
R-HSA-9012852	Signaling by NOTCH3	TAS
R-HSA-9012852	Signaling by NOTCH3	IEA
R-HSA-9013508	NOTCH3 Intracellular Domain Regulates Transcription	TAS
R-HSA-9013508	NOTCH3 Intracellular Domain Regulates Transcription	IEA
R-HSA-9018519	Estrogen-dependent gene expression	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
26300722	Repeated vapor ethanol exposure induces transient histone modifications in the brain that are modified by genotype and brain region. (2015)	Finegersh A	Front Mol Neurosci
27350734	Relationships between cell cycle pathway gene polymorphisms and risk of hepatocellular carcinoma. (2016 Jun 28)	Nan YL	World J Gastroenterol